Your browser doesn't support javascript.
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants.
Miyamoto, Sho; Arashiro, Takeshi; Adachi, Yu; Moriyama, Saya; Kinoshita, Hitomi; Kanno, Takayuki; Saito, Shinji; Katano, Harutaka; Iida, Shun; Ainai, Akira; Kotaki, Ryutaro; Yamada, Souichi; Kuroda, Yudai; Yamamoto, Tsukasa; Ishijima, Keita; Park, Eun-Sil; Inoue, Yusuke; Kaku, Yoshihiro; Tobiume, Minoru; Iwata-Yoshikawa, Naoko; Shiwa-Sudo, Nozomi; Tokunaga, Kenzo; Ozono, Seiya; Hemmi, Takuya; Ueno, Akira; Kishida, Noriko; Watanabe, Shinji; Nojima, Kiyoko; Seki, Yohei; Mizukami, Takuo; Hasegawa, Hideki; Ebihara, Hideki; Maeda, Ken; Fukushi, Shuetsu; Takahashi, Yoshimasa; Suzuki, Tadaki.
  • Miyamoto S; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Arashiro T; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Adachi Y; Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Moriyama S; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Kinoshita H; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Kanno T; Department of Virology I, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Saito S; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Katano H; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Iida S; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Ainai A; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Kotaki R; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Yamada S; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Kuroda Y; Department of Virology I, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Yamamoto T; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Ishijima K; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Park ES; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Inoue Y; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Kaku Y; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Tobiume M; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Iwata-Yoshikawa N; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Shiwa-Sudo N; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Tokunaga K; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Ozono S; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Hemmi T; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Ueno A; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Kishida N; Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Watanabe S; Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Nojima K; Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Seki Y; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, 208-0011, Japan.
  • Mizukami T; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, 208-0011, Japan.
  • Hasegawa H; Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, 208-0011, Japan.
  • Ebihara H; Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
  • Maeda K; Department of Virology I, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Fukushi S; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Takahashi Y; Department of Virology I, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Suzuki T; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Med (N Y) ; 3(4): 249-261.e4, 2022 04 08.
Article in English | MEDLINE | ID: covidwho-1783638
ABSTRACT

Background:

The immune profile against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has dramatically diversified due to a complex combination of exposure to vaccines and infection by various lineages/variants, likely generating a heterogeneity in protective immunity in a given population. To further complicate this, the Omicron variant, with numerous spike mutations, has emerged. These circumstances have created the need to assess the potential of immune evasion by Omicron in individuals with various immune histories.

Methods:

The neutralization susceptibility of the variants, including Omicron and their ancestors, was comparably assessed using a panel of plasma/serum derived from individuals with divergent immune histories. Blood samples were collected from either mRNA vaccinees or from those who suffered from breakthrough infections of Alpha/Delta with multiple time intervals following vaccination.

Findings:

Omicron was highly resistant to neutralization in fully vaccinated individuals without a history of breakthrough infections. In contrast, robust cross-neutralization against Omicron was induced in vaccinees that experienced breakthrough infections. The time interval between vaccination and infection, rather than the variant types of infection, was significantly correlated with the magnitude and potency of Omicron-neutralizing antibodies.

Conclusions:

Immune histories with breakthrough infections can overcome the resistance to infection by Omicron, with the vaccination-infection interval being the key determinant of the magnitude and breadth of neutralization. The diverse exposure history in each individual warrants a tailored and cautious approach to understanding population immunity against Omicron and future variants.

Funding:

This study was supported by grants from the Japan Agency for Medical Research and Development (AMED).
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Med (N Y) Year: 2022 Document Type: Article Affiliation country: J.medj.2022.02.006

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Med (N Y) Year: 2022 Document Type: Article Affiliation country: J.medj.2022.02.006